Reduced effectiveness of long-term interferon-β treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: A Canadian multiple sclerosis clinic-based study

Multiple Sclerosis

Volumn 13, Issue 9, 2007, Pages 1127-1137

  Boz, C ^a   Oger, J ^b,d   Gibbs, E ^b   Grossberg, S E ^c   Devonshire, V ^b   Hashimoto, S ^b   Hooge, J ^b   Smyth, P ^b   Traboulsee, A ^b   Kastrukoff, L ^b  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Binding antibody; Interferon beta; Multiple sclerosis; Neutralizing antibody; Relapse rates

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; AUTOANTIBODY; IMMUNOLOGIC FACTOR;

ADULT; ANTIBODY DETECTION; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; RELAPSE; SINGLE DRUG DOSE; TREATMENT DURATION; BLOOD; DISABILITY; FACTUAL DATABASE; IMMUNOLOGY; MIDDLE AGED; OUTPATIENT DEPARTMENT; RETROSPECTIVE STUDY; STATISTICS; TREATMENT FAILURE;

ADULT; AUTOANTIBODIES; BRITISH COLUMBIA; DATABASES, FACTUAL; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTPATIENT CLINICS, HOSPITAL; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 39549108366     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458507080468     Document Type: Article

References (31)

1. PRISMS. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-36.
2. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-94.
3. Larocca AP, Leung SC, Marcus SG, Colby CB, Borden EC. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser. J Interferon Res 1989; 9(Suppl 1): S51-S60.
4. Oger J, Roos R, Antel JP. Immunology of multiple sclerosis. Neurol Clin 1983; 1: 655-79.
5. Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Bastianelli S, Currenti M et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a. J Interferon Cytokine Res 1998; 18: 345-50.
6. Ross C, Clemmesen KM, Svenson M, Sorensen PS, Koch-Henriksen N, Skovgaard GL et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000; 48: 706-12.
7. Redlich PN, Hoeprich PD, Jr., Colby CB, Grossberg SE. Antibodies that neutralize human beta interferon biologic activity recognize a linear epitope: analysis by synthetic peptide mapping. Proc Natl Acad Sci USA 1991; 88: 4040-4.
8. Runkel L, deDios C, Karpusas M, Baker D, Li Z, Zafari M et al. Mapping of interferon-β epitopes important for receptor binding and activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis. J Interferon Cytokine Res 2001; 21: 931-41.
9. Bertolotto A, Gilli F, Sala A, Capobianco M, Malucchi S, Milano E et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003; 60: 634-9.
10. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999; 52: 1239-43.
11. Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 2004; 62: 2031-7.
12. Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRO). Neurology 1998; 50: 1266-72.
13. Sorensen PS, Ross C, Clemmesen EM, Bendtzen K, Frederiksen JL, Jensen K et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-91.
14. Vallittu AM, Halminen M, Peltoniemi J, Honen J, Julkunen I, Salmi A et al. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients. Neurology 2002; 58: 1786-90.
15. Pachner A, Narayan K, Price N, Hurd M, Dail D. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 2003; 7: 17-25.
16. Pachner AR, Oger J, Palace J. The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta. Neurology 2003; 61: S18-20.
17. Perini P, Calabrese M, Biasi G, Gallo P. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 2004; 251: 305-9.
18. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85.
19. Francis GS, Rice GP, Alsop JC. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48-55.
20. Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999; 52: 1277-9.
21. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003; 61: 551-4.
22. Grossberg SE, Taylor JL, Siebenlist RE, Jameson P. Biological and immunological assays of human interferons. In Manual of Clinical Immunology, third edition. Washington, DC: ASM Publishing, 1986, pp 295-9.
23. Grossberg SE, Kawade Y, Kohase M, Yokoyama H, Finter N. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 2001; 21: 729-42.
24. Grossberg SE, Kawade V, Kohase M, Klein JP. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 2001; 21: 743-55.
25. Sorensen PS, Deisenhammer F, Douda P, Hohlfeld R, Myhr K-M, Palace J et al. Guidelines on use of anti-IFN-β antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817-27.
26. Gibbs E, Oger J. Suggested limits for high and low neutralizing antibody levels in interferon-beta treated multiple sclerosis patients. Mult Scler 2006; 12: S204.
27. Polman C, Kappos L, White R, DahIke F, Beckmann K, Pozzilli C et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 2003; 60: 37-43.
28. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
29. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-9.
30. Oger J, Vorobeychick G, Paty DW. In Betaseron®-treated MS patients, in vitro immune function can be a predictor of neutralizing antibody development. Neurology 1997; 48: A80 (Abstract).
31. Petkau AJ, White RA, Ebers GC, Reder AT, Sibley WA, Lublin FD et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004; 10: 126-38.